Clinical trials
Relapsed or Refractory Peripheral T Cell Lymphoma clinical trials
Below are recruiting relapsed or refractory peripheral t cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,702 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06552416RecruitingPhase 1
Safety study of MT-401-OTS for relapsed AML or MDS
This trial tests a new cell therapy called MT-401-OTS for people aged 65 or older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The goal is to see if this treatment is safe and to find the right dose.
Duarte, CaliforniaAges 65 years+ - NCT06563505RecruitingPhase 2
Study of mosunetuzumab plus zanubrutinib for relapsed marginal zone lymphoma
This trial tests a combination of two drugs (mosunetuzumab and zanubrutinib) for people with marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help control the lymphoma.
Houston, TexasAges 18 years+ - NCT06553053Recruiting
Acupuncture to prevent Crohn's disease relapse
This trial tests if acupuncture can help people with Crohn's disease stay in remission longer and avoid flare-ups. If you are in remission but have had frequent relapses, this study may be for you.
ShanghaiAges 16–75 - NCT06559189RecruitingPhase 1
A new CAR T therapy for children with relapsed B-ALL
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
Aurora, ColoradoAges 3 months–30 years - NCT06430814Recruiting
Blood test to predict nerve damage from paclitaxel
This study looks at whether certain markers in your blood can predict nerve damage from paclitaxel chemotherapy. If you join, researchers will monitor your nerve health during treatment to better understand and possibly prevent side effects.
OdenseAges 18 years+ - NCT06541002Recruiting
SHIFT app for stem cell transplant survivors' sexual health
This trial tests a mobile app (SHIFT) designed to help people who have had a stem cell transplant and are experiencing sexual health concerns. It aims to see if the app can improve your well-being.
Coral Gables, FloridaAges 18 years+ - NCT06508931RecruitingPhase 2
Zamtocabtagene autoleucel for children with B-cell lymphoma or leukemia
This trial tests a new CAR T-cell therapy (zamtocabtagene autoleucel) for children and teens whose B-cell lymphoma or leukemia has come back or hasn't responded to other treatments. The goal is to see if this one-time infusion can help their immune system fight the cancer.
Paris, Boulevard Sérurier 48Ages 6 months–17 years - NCT06481735RecruitingPhase 1/Phase 2
Modified donor CAR-T for B-cell leukemia
This trial tests a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatment. The CAR-T cells are made from a donor and modified to target the CD19 protein on leukemia cells.
Beijing, Beijing MunicipalityAges 16–70 - NCT06469190RecruitingEarly Phase 1
CAR NK cells for treatment-resistant kidney disease
This trial is testing a new therapy made from your own immune cells (called CAR NK cells) that are designed to fight a type of kidney disease that hasn't responded to standard treatments. It may be an option if you have membranous nephropathy, IgA nephropathy, or ANCA-associated vasculitis and previous treatments have failed.
ShanghaiAges 18–70 - NCT06461988RecruitingPhase 2
Talquetamab and lenalidomide after stem cell transplant for myeloma
This trial tests combining two drugs, talquetamab and lenalidomide, as maintenance therapy after a stem cell transplant for multiple myeloma. The goal is to see if this combination helps keep the cancer from coming back.
Palo Alto, CaliforniaAges 18 years+ - NCT06082102RecruitingPhase 3
Comparing orelabrutinib and lenalidomide with rituximab for MZL
This study tests two different drug combinations for people with marginal zone lymphoma that has come back or stopped responding to previous treatment. One group gets orelabrutinib plus rituximab, and the other gets lenalidomide plus rituximab, to see which works better and has fewer side effects.
Bengbu, AuhuiAges 18 years+ - NCT06431633RecruitingPhase 3
Sacituzumab and zimberelimab for lung cancer after surgery
This trial tests a combination of two drugs (sacituzumab and zimberelimab) for people with non-small cell lung cancer that was confined to the chest, was surgically removed, but not completely cleared by prior chemotherapy and immunotherapy. The goal is to see if this treatment can help prevent the cancer from coming back.
Alicante, AlicanteAges 18 years+ - NCT06433752Recruiting
Study of BRIUMVI for relapsing multiple sclerosis
This study looks at how well BRIUMVI (a medicine for relapsing multiple sclerosis) works for people in everyday life. Researchers want to see how people do when they first start the medication.
Birmingham, AlabamaAges 18 years+ - NCT06408259RecruitingPhase 3
Comparing ozanimod and fingolimod for children with MS
This study compares two oral medications, ozanimod and fingolimod, to see which one works better and is safer for children and teenagers with relapsing-remitting MS. Both drugs help reduce MS attacks and slow down the disease.
Loma Linda, CaliforniaAges 10–17 - NCT06383572RecruitingPhase 1/Phase 2
Modified immune cells for blood cancers after chemo
This trial tests a new type of immune cell (NK cell) that has been engineered to target a protein called PRAME found on some cancer cells. It is for people with certain types of blood cancer (AML, MDS, or CMML) that have come back or not responded to treatment.
Houston, TexasAges 18–80 - NCT06343792RecruitingPhase 2
Testing RLS-0071 for steroid-resistant acute graft-versus-host disease
This trial tests a new drug, RLS-0071, for people who are hospitalized with acute graft-versus-host disease that hasn't improved with steroids. It aims to see if the drug is safe and can help control the condition.
Duarte, CaliforniaAges 12 years+ - NCT06345027RecruitingPhase 1
CAR T cell therapy targeting CD70 for leukemia
This trial tests a new treatment made from your own immune cells, called CAR T cells, that are designed to find and attack leukemia cells with a specific marker called CD70. It may be an option if your leukemia has come back or not responded to standard treatments and you might be able to receive a stem cell transplant if this treatment helps.
Houston, TexasAges Up to 75 years - NCT06287944RecruitingPhase 1
Targeted radiation and chemo before donor stem cell transplant
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
Duarte, CaliforniaAges 18–70 - NCT06287229RecruitingPhase 1/Phase 2
CAR T therapy for B-cell ALL after initial treatment
This trial tests whether a special immune cell therapy (brexucabtagene autoleucel, or CAR T therapy) can help people with B-cell acute lymphocytic leukemia (ALL) after reducing the number of leukemia cells with a chemo-immunotherapy combination. It is for patients whose cancer has returned or is hard to treat, or for those newly diagnosed with a high-risk form of ALL.
Houston, TexasAges 18 years+ - NCT06252792Recruiting
Daratumumab-pomalidomide-dexamethasone for first-relapse myeloma
This trial tests a combination of three drugs (daratumumab, pomalidomide, and dexamethasone) for people whose multiple myeloma has returned for the first time after initial treatment with RVD. The goal is to see if this new combination can control the cancer.
Changchun, JilinAges 18 years+ - NCT06234904RecruitingPhase 1
IBR733 cell therapy for acute myeloid leukemia
This trial tests a new cell treatment called IBR733 for people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The goal is to see if it is safe and helps fight the leukemia.
Suzhou, JiangsuAges 18–74 - NCT06223074Enrolling by invitationPhase 2
Nasal Steroid Spray for MS Relapses
This study tests a nasal spray form of the steroid methylprednisolone for treating MS relapses. The goal is to see if this new way of taking the medicine works as well or better than standard treatments.
Mexico CityAges 18–65 - NCT06207123RecruitingPhase 1/Phase 2
New drug combo for T-cell leukemia or lymphoma
This trial tests a new combination of drugs (LP-118, ponatinib, vincristine, and dexamethasone) for people with T-cell leukemia or lymphoma that has returned or not responded to prior treatments. The goal is to see if this combination can help control the disease.
Chicago, IllinoisAges 18 years+ - NCT06198296RecruitingPhase 1
Armored CAR T cells for GPC3-positive solid tumors
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
Houston, TexasAges Up to 21 years
Hear when a new Relapsed or Refractory Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory peripheral t cell lymphoma?
- Yes. Clin2 currently lists 1,702 recruiting relapsed or refractory peripheral t cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory peripheral t cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory peripheral t cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed Peripheral T-Cell Lymphoma
- Relapsed or Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.